BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bilessglu (Chiglitazar) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bilessglu (Chiglitazar)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06773221-294@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Bilessglu (Chiglitazar): Phase na readout est. (NCT06773221)
DESCRIPTION:Bilessglu (Chiglitazar)\, phase na.\nStudy: The Efficacy and Sa
 fety of Chiglitazar in Patients with MAFLD-related Cirrhosis\nEstimated pr
 imary completion: 31 January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/chiglitazar#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06773221
URL:https://assetmemo.bio/drug/chiglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783100-294@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Bilessglu (Chiglitazar): Phase 2 readout est. (NCT07783100)
DESCRIPTION:Bilessglu (Chiglitazar)\, phase 2.\nStudy: Venetoclax\, Chidami
 de\, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acu
 te Myeloid Leukemia\nEstimated primary completion: 31 March 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/chiglitazar#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07783100
URL:https://assetmemo.bio/drug/chiglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07558525-294@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bilessglu (Chiglitazar): Phase na readout est. (NCT07558525)
DESCRIPTION:Bilessglu (Chiglitazar)\, phase na.\nStudy: Evaluation of Chigl
 itazar Sodium With Lifestyle Intervention for Reversing Prediabetes\nEstim
 ated primary completion: 31 December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/chiglitazar#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07558525
URL:https://assetmemo.bio/drug/chiglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07303803-294@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Bilessglu (Chiglitazar): Phase 2 readout est. (NCT07303803)
DESCRIPTION:Bilessglu (Chiglitazar)\, phase 2\, Type 2 Diabetes.\nStudy: A 
 Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Ste
 atohepatitis and Type 2 Diabetes Mellitus\nEstimated primary completion: 1
  December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/chigl
 itazar#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07303803
URL:https://assetmemo.bio/drug/chiglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
